A phase 3 randomized, double-blind, placebo controlled, multicenter, parallel group study to assess the efficacy and safety of fixed-dose combination RHB-104 in subjects with moderately to severely active Crohn's disease.
You may qualifity to participate if:
* Age 18 to 65
* Crohns disease diagnosed by endoscopy or radiography at least 6 months prior to study enrollment
Qualified participants may receive study medicatin, study related medical care, and payment for completed visits